Loading
Life sciences · Journal article
Cancer Research · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical mechanistic study proposing that MET exon 14 skipping drives tumorigenesis by abolishing dependence receptor-mediated apoptosis, not merely by enhancing oncogenic signaling. Using genome editing in mouse models, the authors show that restoration of the pro-apoptotic p40MET fragment can resensitize tumors to capmatinib, but no human efficacy data are presented.
Mechanistic study with genome editing and mouse models. Cell lines and HGF-humanized mouse models; no human patients described. Intervention: Genome editing to remove caspase cleavage site and/or CBL-binding motif; inducible re-expression of p40MET; capmatinib treatment. Compared with: Individual mutations of caspase or CBL sites; METex14Del-expressing cells without p40MET re-expression.
METex14Del removes both caspase cleavage site and CBL-binding motif, preventing p40MET fragment generation while sustaining oncogenic MET signaling Combined mutation of caspase and CBL sites—but not individual mutations—recapitulated resistance to apoptosis and tumor growth in HGF-humanized mouse models Inducible re-expression of p40MET in METex14Del-expressing cells restored apoptotic sensitivity, decreased tumor formation in vivo, and resensitized tumors to capmatinib
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work proposes a rationale for why kinase inhibitors targeting MET signaling alone may have limited efficacy in METex14Del tumors, and identifies restoration of dependence receptor function as a potential therapeutic strategy. However, no clinical trial evidence or human efficacy data are provided, so clinical applicability remains speculative.
Mechanistic study using genome editing and mouse models to propose a novel oncogenic mechanism; lacks clinical trial data or human efficacy evidence for therapeutic translation.
As stated by the source record.
This work proposes a rationale for why kinase inhibitors targeting MET signaling alone may have limited efficacy in METex14Del tumors, and identifies restoration of dependence receptor function as a potential therapeutic strategy. However, no clinical trial evidence or human efficacy data are provided, so clinical applicability remains speculative.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Receptor tyrosine kinases (RTKs) classically function as oncogenic drivers that promote survival and proliferation upon ligand binding. A subset of RTKs can also function as dependence receptors, inducing apoptosis in the absence of their ligands. Genetic alterations that enhance RTK signaling are well characterized in cancer and can be targeted with kinase inhibitors, which show limited efficacy in some clinical settings. Elucidation of whether oncogenic mutations can promote tumorigenesis by directly abolishing the pro-apoptotic activity of dependence receptors could help improve strategies to target RTKs. Here, we identified MET exon 14 skipping (METex14Del) as a paradigmatic example of an oncogenic alteration that drives tumorigenesis through genetic inactivation of the dependence receptor function of an RTK. METex14Del removed both the caspase cleavage site and adjacent CBL-binding motif, preventing generation of the pro-apoptotic p40MET fragment while sustaining oncogenic MET signaling. Uncoupling regulatory functions of MET using genome editing showed that loss of apoptosis capacity is a critical determinant of METex14Del-driven tumorigenesis. Combined—but not individual—mutation of the caspase and CBL sites was sufficient to recapitulate resistance to apoptosis and tumor growth induced by METex14Del in HGF-humanized mouse models. Importantly, inducible re-expression of p40MET in METex14Del-expressing cells restored apoptotic sensitivity, decreased tumor formation in vivo, and resensitized tumors to capmatinib. Together, these findings redefine RTKs as receptors with dual oncogenic and tumor-suppressive functions and show that disruption of dependence receptor–mediated apoptosis is an oncogenic mechanism. These results provide a conceptual framework explaining why therapies targeting only RTK signaling may fail and support strategies restoring dependence receptor function to achieve durable tumor suppression.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.